TOPLINE:

GLP-1 receptor agonists (RAs) cut cardiovascular risks among patients with type 2 diabetes (T2D) and atopic dermatitis (AD) in this analysis.

METHODOLOGY:

Analysis included 17,099 propensity score-matched patient pairs with T2D, with or without AD (mean age, 53 years; 67% women), in the TriNetX Linked network between 2015 and 2025, including pairs treated with GLP-1 RAs.

About 36% of patients were White, 24% were Black, 5% were Asian, and 9% were Hispanic or Latino individuals.

Primary outcomes included all-cause mortality, new-onset major adverse cardiovascular events (MACE), myocardial infarction (MI), heart failure, and ischemic stroke within 10 years.

TAKEAWAY:

Patients with AD vs those without AD showed higher risks for MI (hazard ratio [HR], 1.17; P = .001), heart f

See Full Page